EuropaBio has published the National Associations Council Summit 2022 Event Report ''Biotechnology: Delivering Europe’s industrial strategy across the sectors''. The report includes key policy recommendations for healthcare and industrial biotechnology sectors at national and the EU level which could serve the policymakers to get a better understanding of the sector’s potential and regulatory challenges in operating on the national and EU level.
The ultimate aim of drug development is for patients to access lifesaving and life-enhancing new medicines, but for many of the most innovative new medicines, securing access for NHS patients is a long and difficult process. One of the most promising new areas of medicine is cell and gene therapies, which have potential to address complex diseases, including many rare diseases for which there are no effective treatments. However, these treatments face challenges in securing patient access because of high up-front cost and uncertainty about long-term outcomes.
Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.
“Women can punch the leadership weight and make a real difference in the sector. Here, we’re bringing different generations of women together to showcase that there’s already a fantastic contribution from women in life sciences.”
Many of you will be aware that there have been reports this week from the World Trade Organisation in Geneva that the EU, South Africa, India and the US are agreeing a compromise on the waiver of intellectual property rights on COVID-19 vaccines. The key part of the compromise would be that developing countries that have exported less than 10% of the world’s vaccines in 2021, (so India but not China) would be able to authorise the use of a patented coronavirus vaccine without the patent owner’s consent.
I was delighted to represent the UK sector at the Coalition for Epidemic Preparedness Innovations (CEPI) Global Pandemic Preparedness Summit, with partners and colleagues from across the global life sciences sector. Read more for key takeaways from the conference, as well as supporting aspiring entrepreneurs and CEOs in life sciences through PULSE 2022, Cytiva opening a new Cardiff manufacturing facility and COVID-19 vaccines waiver.
Herbie Lambden recently joined the BIA team as Policy and Public Affairs Executive. In this blog, he shares his experience and key takeaways from the BIA Committee Summit which took place on 24th February.